Federal Marijuana Regulation: Laws, Scheduling, and Reform Efforts

Executive Summary

Federal marijuana regulation in the United States remains in a state of legal contradiction as of July 2026, with cannabis classified as a Schedule I controlled substance under the Controlled Substances Act while 38 states have legalized medical use and 24 states permit adult recreational consumption. The federal government's enforcement posture has evolved dramatically since the Obama administration's Cole Memorandum in 2013, yet Congress has not passed comprehensive reform legislation despite bipartisan support for banking access and veterans' medical cannabis rights. The Drug Enforcement Administration initiated a rescheduling process in 2024 following a Department of Health and Human Services recommendation to move cannabis to Schedule III, a proceeding that remains pending before an administrative law judge as of mid-2026. This regulatory limbo creates operational challenges for state-licensed businesses unable to access traditional banking services, forces operators to pay effective tax rates exceeding 70% under Internal Revenue Code Section 280E, and leaves patients in legal states vulnerable to federal prosecution despite practical non-enforcement. The economic stakes are substantial: the legal cannabis industry generated $33.6 billion in sales during 2025, employed over 428,000 workers, and contributed $15.9 billion in combined state and local tax revenue, yet remains excluded from interstate commerce and federal trademark protection.

Why Federal Marijuana Regulation Matters

The federal prohibition of marijuana affects 161 million Americans living in legal states, creates a $33.6 billion industry operating in legal gray zones, and forces medical patients to choose between federal benefits and state-legal treatment. The conflict between state and federal marijuana law creates cascading consequences across multiple sectors. State-licensed cannabis businesses in California, Colorado, Michigan, and other legal jurisdictions cannot access FDIC-insured banking services because financial institutions face potential prosecution under 18 U.S.C. § 1956 (money laundering) and 18 U.S.C. § 1957 (monetary transactions in property derived from unlawful activity). This forces approximately 62% of dispensaries to operate primarily in cash as of 2025, creating public safety risks and tax compliance challenges. Military veterans comprise a particularly affected population. The Department of Veterans Affairs cannot recommend or provide cannabis treatment despite 37 states legalizing medical marijuana for PTSD, a condition affecting an estimated 13% of veterans. Veterans who use state-legal cannabis risk losing VA benefits, federal employment eligibility, and concealed carry permits under 18 U.S.C. § 922(g)(3), which prohibits firearm possession by unlawful drug users. The economic scale is substantial. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs collectively operate over 900 dispensaries across legal states but cannot deduct ordinary business expenses under 26 U.S.C. § 280E, which disallows deductions for businesses trafficking in Schedule I or II controlled substances. This tax treatment results in effective federal tax rates between 70-90% of gross profit, constraining capital for expansion and creating competitive disadvantages against illicit market operators who pay no taxes. Medical patients face access barriers despite state legalization. Federal employees, including those working for agencies like the DEA and FDA, cannot use medical marijuana without risking termination. Public housing residents can be evicted under federal housing rules. Organ transplant candidates at federally funded hospitals have been denied placement on waiting lists for testing positive for THC.

Background and History: The Path to Federal Prohibition

Federal marijuana regulation began with the Marihuana Tax Act of 1937 and evolved through the Controlled Substances Act of 1970 into the current Schedule I classification that defines cannabis as having no accepted medical use and high abuse potential.

Early Federal Regulation: 1906-1937

Cannabis was widely available in American pharmacies throughout the 19th and early 20th centuries, included in patent medicines and prescribed for conditions ranging from migraines to menstrual cramps. The Pure Food and Drug Act of 1906 required labeling of cannabis content but did not prohibit sale or possession. State-level prohibition began earlier than federal action. California enacted the first state cannabis prohibition in 1913, followed by Wyoming, Texas, and Nevada by 1915. By 1931, 29 states had prohibited cannabis, driven partly by anti-Mexican immigrant sentiment and concerns about recreational use among minority populations.

The Marihuana Tax Act of 1937

Federal prohibition effectively began with the Marihuana Tax Act of 1937, championed by Federal Bureau of Narcotics Commissioner Harry Anslinger. The Act imposed prohibitive taxes and registration requirements on cannabis cultivation, distribution, and possession, making legal compliance practically impossible while maintaining technical legality. The American Medical Association opposed the Act, with legislative counsel Dr. William Woodward testifying that the legislation would ultimately prevent medical use. The Supreme Court struck down the Marihuana Tax Act in Leary v. United States, 395 U.S. 6 (1969), ruling that the Act's registration requirements violated Fifth Amendment protections against self-incrimination.

The Controlled Substances Act: 1970

Congress replaced the invalidated Tax Act with the Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.), which established five schedules of controlled substances based on medical use, abuse potential, and safety. The Act temporarily placed marijuana in Schedule I pending a commission review. The National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond Shafer, issued its report "Marihuana: A Signal of Misunderstanding" in 1972, recommending decriminalization of personal possession and use. President Richard Nixon rejected the commission's findings, and marijuana remained in Schedule I, defined by three criteria: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision.

State Medical Marijuana Movement: 1996-2012

California voters approved Proposition 215 (the Compassionate Use Act) in November 1996, becoming the first state to legalize medical marijuana since federal prohibition. The initiative allowed patients with a physician's recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, glaucoma, and chronic pain. The federal response was immediate enforcement. The Department of Justice under Attorney General Janet Reno announced that physicians recommending marijuana could face DEA license revocation. This policy was challenged in Conant v. Walters, with the Ninth Circuit ruling in 2002 that the First Amendment protected physician-patient discussions about medical marijuana. The Supreme Court addressed state-federal conflict in Gonzales v. Raich, 545 U.S. 1 (2005), ruling that Congress could prohibit intrastate cultivation and possession of marijuana under the Commerce Clause even in states that legalized medical use. The decision affirmed federal supremacy but did not require states to enforce federal prohibition. By 2012, 18 states and the District of Columbia had enacted medical marijuana programs despite continued federal Schedule I classification.

Adult-Use Legalization and Federal Enforcement Evolution: 2012-2018

Colorado and Washington voters approved adult-use legalization initiatives in November 2012, creating the first regulated recreational marijuana markets. Amendment 64 in Colorado and Initiative 502 in Washington established state licensing systems for cultivation, manufacturing, testing, and retail sale to adults 21 and older. The Obama administration responded with the Cole Memorandum in August 2013, issued by Deputy Attorney General James Cole. The memorandum deprioritized federal enforcement in states with robust regulatory systems, identifying eight enforcement priorities including preventing distribution to minors, preventing revenue to criminal enterprises, and preventing drugged driving. The Cole Memorandum did not change federal law but provided prosecutorial discretion guidance to U.S. Attorneys. The FinCEN guidance issued in February 2014 provided limited safe harbor for financial institutions serving state-licensed marijuana businesses, establishing "marijuana limited" and "marijuana priority" Suspicious Activity Report categories. However, most major banks continued to refuse cannabis industry accounts due to ongoing federal illegality. Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, returning enforcement discretion to individual U.S. Attorneys. Despite the rescission, federal prosecutions of state-compliant marijuana businesses remained rare, with the Justice Department focusing resources on operations violating state law or involving violence.

Congressional Action and Inaction: 2014-2024

Congress has enacted limited protections through annual appropriations riders. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), first passed in 2014 and renewed annually, prohibits the Department of Justice from using funds to prevent states from implementing medical marijuana laws. The Ninth Circuit interpreted this amendment in United States v. McIntosh, 833 F.3d 1163 (2016), as barring prosecution of individuals complying with state medical marijuana law. The SAFE Banking Act, first introduced in 2019, passed the House of Representatives seven times between 2019-2024 but never received a Senate floor vote despite bipartisan support. The legislation would provide safe harbor for financial institutions serving state-licensed cannabis businesses and allow the Federal Reserve to process transactions. The Medical Marijuana and Cannabidiol Research Expansion Act became law in December 2022, the first standalone marijuana reform legislation enacted by Congress since the Controlled Substances Act. The law streamlined the DEA registration process for researchers and required HHS to issue guidance on cannabidiol research within one year. The MORE Act (Marijuana Opportunity Reinvestment and Expungement Act) passed the House in 2020 and 2022 but did not advance in the Senate. The legislation would deschedule cannabis entirely, expunge federal marijuana convictions, and impose a 5% federal excise tax with revenue directed to communities disproportionately affected by prohibition.

The Rescheduling Process: 2022-Present

President Joe Biden issued a presidential memorandum in October 2022 directing HHS Secretary Xavier Becerra and Attorney General Merrick Garland to review marijuana's Schedule I classification. Biden simultaneously issued categorical pardons for federal simple marijuana possession convictions, affecting approximately 6,500 individuals. HHS completed its review in August 2023, recommending to the DEA that marijuana be rescheduled to Schedule III based on analysis of abuse potential, medical use, and international treaty obligations. The recommendation cited FDA-approved cannabidiol medications, state medical marijuana programs serving over 6 million registered patients, and lower abuse potential compared to Schedule I and II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, formally proposing to reschedule marijuana to Schedule III. The proposal triggered a 60-day public comment period that received over 43,000 submissions from medical professionals, patients, industry stakeholders, law enforcement, and advocacy organizations. Administrative law judge hearings on the rescheduling proposal began in November 2024 and continue as of July 2026. Schedule III classification would maintain federal prohibition of non-medical use but recognize accepted medical use, allow FDA-approved cannabis medications, and eliminate 280E tax penalties for state-licensed businesses. Cannabis would remain a controlled substance subject to DEA manufacturing quotas and distribution controls.

Key Players in Federal Marijuana Regulation

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule controlled substances and enforce the Controlled Substances Act, making it the primary federal agency determining marijuana's legal status. The agency operates the Cannabis Eradication Program, which destroyed 6.3 million cultivated outdoor plants and 467,000 indoor plants in 2023. DEA Administrator Anne Milgram oversees the ongoing rescheduling proceeding and has stated that the agency will follow the science-based recommendation from HHS while ensuring compliance with international treaty obligations under the Single Convention on Narcotic Drugs. The DEA issues annual manufacturing quotas for Schedule I and II controlled substances. The agency increased the marijuana research quota from 472 kilograms in 2018 to 3,200 kilograms in 2023 to accommodate expanded research under the Medical Marijuana and Cannabidiol Research Expansion Act.

Department of Health and Human Services and Food and Drug Administration

HHS provides scientific and medical evaluations to the DEA for scheduling decisions under 21 U.S.C. § 811(b). The FDA, an HHS component agency, conducted the comprehensive review that resulted in the August 2023 Schedule III recommendation. FDA Commissioner Robert Califf has emphasized that rescheduling does not make marijuana an FDA-approved drug and that cannabis products would require standard new drug applications demonstrating safety and efficacy. The FDA has approved four cannabis-derived or cannabis-related medications: Epidiolex (cannabidiol) for seizure disorders associated with Lennox-Gastaut syndrome and Dravet syndrome, and synthetic THC medications Marinol, Syndros, and Cesamet for chemotherapy-induced nausea and AIDS-related wasting syndrome.

Department of Justice

The Justice Department prosecutes federal marijuana offenses and issues enforcement guidance to U.S. Attorneys. The department has maintained a hands-off approach to state-compliant marijuana businesses since 2013 despite the 2018 Cole Memorandum rescission. Federal marijuana prosecutions declined from 9,866 in 2012 to 3,948 in 2023, with the majority involving large-scale trafficking operations or firearms violations rather than state-compliant activity.

Internal Revenue Service

The IRS enforces 26 U.S.C. § 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. The agency issued guidance in Chief Counsel Advice 201504011 clarifying that cannabis businesses can deduct cost of goods sold but not operating expenses including rent, employee salaries, marketing, or utilities. IRS audits of cannabis businesses increased 37% between 2020-2023, with the agency pursuing approximately $1.8 billion in additional assessments.

Multi-State Operators

Curaleaf operates 151 dispensaries across 18 states and reported $1.38 billion in revenue for 2025. The company has advocated for SAFE Banking Act passage and federal descheduling while maintaining compliance with state regulations. Trulieve operates 196 dispensaries primarily concentrated in Florida and reported $1.26 billion in 2025 revenue. The company spent $43 million supporting Florida's adult-use legalization initiative in 2024. Green Thumb Industries operates 93 retail locations across 15 states under the RISE and Essence brands, reporting $1.07 billion in 2025 revenue. Cresco Labs operates 58 dispensaries across 10 states and owns wholesale brands including Mindy's Edibles and Remedi. The company reported $823 million in 2025 revenue.

Advocacy Organizations

The National Organization for the Reform of Marijuana Laws, founded in 1970, advocates for complete federal descheduling and has coordinated lobbying efforts for the MORE Act and SAFE Banking Act. The Marijuana Policy Project focuses on state-level legalization campaigns and federal legislative reform. The organization helped draft and pass legalization initiatives in Colorado, Nevada, and Montana. Americans for Safe Access concentrates on medical marijuana patient rights and has submitted detailed comments in the DEA rescheduling proceeding supporting Schedule III classification as an interim step toward descheduling.

Opposition Groups

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposes legalization and commercialization while supporting decriminalization and medical research. The organization submitted comments to the DEA opposing rescheduling and citing concerns about youth access and impaired driving. The Community Anti-Drug Coalitions of America represents over 5,000 community coalitions and has opposed federal legalization while supporting continued Schedule I classification.

Legal and Regulatory Framework

Federal marijuana prohibition rests on the Controlled Substances Act's Schedule I classification, which defines cannabis as having high abuse potential, no accepted medical use, and inadequate safety for medical supervision, creating direct conflict with 38 state medical marijuana programs and 24 adult-use legalization states. The Controlled Substances Act establishes five schedules at 21 U.S.C. § 812. Schedule I substances must meet three criteria: (A) high potential for abuse, (B) no currently accepted medical use in treatment in the United States, and (C) lack of accepted safety for use under medical supervision. Schedule III substances have lower abuse potential than Schedule I and II, currently accepted medical use, and moderate or low physical dependence or high psychological dependence potential. Federal marijuana offenses are prosecuted under 21 U.S.C. § 841 (manufacturing, distribution, possession with intent to distribute) and 21 U.S.C. § 844 (simple possession). Penalties vary based on quantity, with cultivation or distribution of 1,000 kilograms or more carrying a 10-year mandatory minimum sentence and up to life imprisonment. Simple possession carries a maximum one-year sentence and $1,000 fine for first offense. The Supremacy Clause of Article VI establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine established in Printz v. United States, 521 U.S. 898 (1997), prevents the federal government from requiring states to enforce federal prohibition. States can legalize marijuana under state law without violating federal law, but state legalization does not provide immunity from federal prosecution. The Commerce Clause grants Congress authority to regulate interstate commerce and activities substantially affecting interstate commerce. Gonzales v. Raich affirmed that this authority extends to intrastate marijuana cultivation and possession because of aggregate effects on the national marijuana market. The Rohrabacher-Blumenauer Amendment, codified in annual appropriations acts, provides that none of the funds made available to the Department of Justice may be used to prevent states from implementing medical marijuana laws. The Ninth Circuit interpreted this in United States v. McIntosh as barring prosecution of individuals in strict compliance with state medical marijuana law, but the protection expires if the appropriations rider is not renewed. International treaty obligations complicate federal reform. The United States is party to the 1961 Single Convention on Narcotic Drugs, which requires signatories to limit cannabis to medical and scientific purposes. The treaty includes a denunciation procedure allowing withdrawal with six months' notice, the path taken by Bolivia to permit traditional coca leaf use and by Canada before implementing adult-use legalization in 2018.

State-by-State Status

As of July 2026, 24 states and the District of Columbia have legalized adult-use marijuana, 38 states permit medical use, and 12 states maintain comprehensive prohibition, creating a patchwork of conflicting regulations that federal law does not preempt but does not recognize.

State	Medical Status	Adult-Use Status	Possession Limit (Adult-Use)	Home Cultivation
Alaska	Legal (1998)	Legal (2015)	1 oz	6 plants
Arizona	Legal (2010)	Legal (2021)	1 oz	6 plants
California	Legal (1996)	Legal (2018)	1 oz	6 plants
Colorado	Legal (2000)	Legal (2014)	1 oz	6 plants
Connecticut	Legal (2012)	Legal (2023)	1.5 oz	6 plants (2024)
Delaware	Legal (2011)	Legal (2025)	1 oz	Prohibited
Florida	Legal (2016)	Prohibited	N/A	Prohibited
Illinois	Legal (2014)	Legal (2020)	30g	5 plants (medical only)
Maine	Legal (1999)	Legal (2020)	2.5 oz	6 plants
Maryland	Legal (2014)	Legal (2023)	1.5 oz	2 plants
Massachusetts	Legal (2012)	Legal (2018)	1 oz	6 plants
Michigan	Legal (2008)	Legal (2019)	2.5 oz	12 plants
Missouri	Legal (2018)	Legal (2023)	3 oz	6 plants
Montana	Legal (2004)	Legal (2023)	1 oz	4 plants
Nevada	Legal (2000)	Legal (2017)	1 oz	6 plants (if 25+ miles from dispensary)
New Jersey	Legal (2010)	Legal (2022)	1 oz	Prohibited
New Mexico	Legal (2007)	Legal (2022)	2 oz	6 plants
New York	Legal (2014)	Legal (2023)	3 oz	6 plants
Ohio	Legal (2016)	Legal (2024)	2.5 oz	6 plants
Oregon	Legal (1998)	Legal (2015)	1 oz	4 plants
Pennsylvania	Legal (2016)	Prohibited	N/A	Prohibited
Rhode Island	Legal (2006)	Legal (2024)	1 oz	6 plants
Vermont	Legal (2004)	Legal (2022)	1 oz	6 plants
Virginia	Legal (2020)	Legal (2024)	1 oz	4 plants
Washington	Legal (1998)	Legal (2014)	1 oz	Prohibited (medical only)

California

California operates the largest legal marijuana market in the United States, with $5.3 billion in licensed sales during 2025. The state's Medicinal and Adult-Use Cannabis Regulation and Safety Act established the Department of Cannabis Control as the unified licensing authority in 2021, consolidating previously fragmented oversight. California imposes a 15% excise tax on retail sales plus local taxes that can reach 10% in cities like Los Angeles and San Francisco. The state faces ongoing challenges from a large illicit market estimated at $8.7 billion annually, driven partly by high tax rates and local cultivation bans in 62% of jurisdictions.

New York

New York legalized adult-use marijuana through the Marijuana Regulation and Taxation Act in March 2021, but retail sales did not begin until December 2022 due to regulatory delays and litigation. The state prioritizes social equity applicants, reserving the first 150 retail licenses for individuals with prior marijuana convictions or their family members. New York imposes a 13% sales tax plus 9% THC-based tax on flower and concentrate products. The state's Office of Cannabis Management reported $267 million in licensed sales during 2025, while estimates place illicit market sales at over $3 billion.

Texas

Texas maintains some of the strictest marijuana laws in the nation, with possession of any amount classified as a criminal offense. The state's Compassionate Use Program, enacted in 2015 and expanded in 2019 and 2021, permits low-THC cannabis (0.5% THC or less) for patients with qualifying conditions including epilepsy, PTSD, cancer, and autism. Only three licensed dispensaries serve the entire state as of 2026. Possession of two ounces or less is a Class B misdemeanor carrying up to 180 days in jail and a $2,000 fine.

Florida

Florida voters rejected Amendment 3, an adult-use legalization initiative, in November 2024 with 57% support, falling short of the 60% threshold required for constitutional amendments. The state's medical marijuana program, established by Amendment 2 in 2016, serves over 890,000 registered patients as of 2026, the third-largest medical program nationally. Florida does not impose purchase limits for medical patients and permits smokable flower, edibles, concentrates, and topicals. The state's vertical integration requirement mandates that licensed Medical Marijuana Treatment Centers handle cultivation, processing, and retail operations.

Market and Business Implications

Federal prohibition forces state-licensed cannabis businesses to operate without banking access, pay effective tax rates exceeding 70%, and remain excluded from interstate commerce, creating a $33.6 billion industry structured fundamentally differently from other legal sectors. The 280E tax burden represents the most significant financial challenge for cannabis operators. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Cannabis retailers can deduct cost of goods sold under Treas. Reg. § 1.61-3(a) but cannot deduct rent, employee salaries (except for employees directly handling inventory), marketing, utilities, or professional services. This results in effective federal tax rates between 70-90% of gross profit compared to 21-37% for comparable non-cannabis retailers. Rescheduling to Schedule III would eliminate 280E penalties, potentially reducing tax burdens by $1.8-2.3 billion annually across the industry according to analysis by cannabis accounting firm Viridian Capital Advisors. This capital could fund expansion, price reductions to compete with illicit markets, and employee compensation increases. Banking access remains severely limited despite the 2014 FinCEN guidance. Approximately 749 banks and credit unions served cannabis businesses as of Q4 2025 according to FinCEN data, representing 6.8% of federally insured institutions. Most major national banks including JPMorgan Chase, Bank of America, and Wells Fargo maintain blanket prohibitions on cannabis accounts. Regional and state-chartered institutions that serve the industry charge premium fees ranging from $2,000-5,000 monthly for basic checking accounts plus 2-4% of deposits. The cash-intensive operating environment creates public safety risks and operational inefficiencies. Dispensaries maintain armed security, armored car services for tax payments, and sophisticated cash management systems. Colorado reported 112 burglaries of licensed marijuana businesses in 2025, with thieves targeting cash rather than inventory in 68% of incidents. Capital markets access is constrained by federal illegality. U.S. cannabis companies cannot list on the New York Stock Exchange or Nasdaq, forcing them to trade on the Canadian Securities Exchange or over-the-counter markets with less liquidity and institutional investor participation. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs all trade on the CSE with American Depositary Receipts available over-the-counter. Debt financing costs significantly exceed rates for comparable legal businesses. Cannabis operators pay interest rates of 12-18% for senior secured debt compared to 5-8% for similarly sized retail or manufacturing companies. Lenders price in federal illegality risk, limited collateral options due to inability to perfect security interests across state lines, and potential asset forfeiture. Interstate commerce prohibition fragments the national market into 38 separate state markets with independent supply chains. California cultivators cannot ship surplus inventory to undersupplied markets in New York or Illinois. This creates price disparities, with wholesale flower ranging from $800-1,200 per pound in Oregon and Washington to $2,400-3,200 per pound in New York and New Jersey as of Q2 2026. Federal descheduling would enable interstate commerce under the dormant Commerce Clause, potentially reducing prices 30-40% in high-cost markets while providing revenue opportunities for efficient cultivators in mature markets. Intellectual property protection is unavailable at the federal level. The U.S. Patent and Trademark Office refuses trademark registration for cannabis products under the Lanham Act because use in commerce requires violation of the Controlled Substances Act. Operators rely on state-level trademark registration and common law rights, which do not prevent infringement in other states. This enables brand confusion and counterfeiting, with popular brands like Cookies, Stiiizy, and Jeeter facing widespread unauthorized use of their marks.

What Experts Say

Medical researchers, economists, law enforcement officials, and policy analysts offer divergent perspectives on federal marijuana regulation, with consensus emerging on banking access and research barriers but sharp disagreement on appropriate regulatory frameworks. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has stated that marijuana's Schedule I classification impedes research into both therapeutic potential and health risks. According to testimony before the Senate Caucus on International Narcotics Control in 2023, the current regulatory framework creates barriers to studying cannabis effects on adolescent brain development, addiction treatment, and pain management. Volkow has noted that rescheduling to Schedule III would maintain research oversight while reducing administrative barriers. The American Medical Association adopted policy in 2019 supporting rescheduling marijuana to facilitate research and permit physician-patient discussions without fear of federal sanction. The organization's Council on Science and Public Health concluded that available evidence supports medical use for chronic pain, chemotherapy-induced nausea, and spasticity associated with multiple sclerosis. Law enforcement perspectives vary significantly. The Major Cities Chiefs Association, representing police leadership from 80 large U.S. cities, has opposed legalization and supported continued Schedule I classification, citing concerns about impaired driving, youth access, and organized crime involvement in legal markets. The organization's 2024 position paper stated that legalization has not eliminated illicit markets and has created regulatory challenges for local law enforcement. Conversely, Law Enforcement Action Partnership, representing current and former police, prosecutors, and judges, has advocated for federal descheduling and regulation. The organization's executive director, Major Neill Franklin (retired), has stated that prohibition directs law enforcement resources toward non-violent marijuana offenses while failing to prevent youth access or reduce availability. Economic analysis from the Congressional Budget Office estimated in 2022 that federal marijuana legalization with a 25% excise tax would generate $8.5-13.2 billion in annual federal tax revenue while reducing federal incarceration costs by $800 million annually. The analysis noted that revenue estimates carry significant uncertainty based on illicit market persistence, tax rate effects on legal market share, and interstate commerce effects. The Cato Institute, a libertarian think tank, has published research supporting complete federal descheduling and state-level regulatory authority. Senior fellow Jeffrey Miron's 2023 analysis concluded that federal prohibition generates enforcement costs exceeding $7 billion annually while creating opportunities for organized crime and preventing quality control and consumer protection. Public health researchers at Johns Hopkins Bloomberg School of Public Health have recommended federal regulation modeled on alcohol and tobacco frameworks, with restrictions on marketing to minors, pot